Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. (Q38566770)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

meta-analysis

0 references

title

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Hesham ElHalawani

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Mona Fouad

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

14 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

2471-2484

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab in patients with cancer and the management of dermatologic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.118

21 January 2018

Identifiers

DOI

10.2217/FON.15.118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26274495%20AND%20SRC:MED&resulttype=core&format=json